Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
Top Page
TG Therapeutics
(NASDAQ:TGTX)
58Neutral
Positive Factors
Market Potential
Record enrollments into the company's hub were observed, indicating strong demand and potential for further growth.
Sales Performance
Briumvi U.S. net product revenue for 4Q24 and FY24 showed significant growth, with FY24 revenue up approximately 250% year over year.
Negative Factors
Competitive Challenges
There are competitive headwinds expected to strengthen for Briumvi with the introduction of subq use of Kesimpta and Ocrevus.
TG Therapeutics (TGTX) vs. S&P 500 (SPY)
Market Cap
$6.16B
Dividend YieldN/A
Average Volume (3M)2.52M
Price to Earnings (P/E)281.0
Beta (1Y)2.07
Revenue Growth40.80%
EPS Growth100.62%
CountryUS
Employees338
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)0.14
Shares Outstanding157,070,570
10 Day Avg. Volume4,090,355
30 Day Avg. Volume2,524,419
Financial Highlights & Ratios
PEG Ratio2.79
Price to Book (P/B)N/A
Price to Sales (P/S)22.80
Price to Cash Flow (P/CF)-123.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$42.80Price Target Upside13.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
TG Therapeutics Business Overview & Revenue Model
Company DescriptionTG Therapeutics, Inc. (TGTX) is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company's core products include FDA-approved therapies such as ublituximab and umbralisib, which are used in the treatment of certain blood cancers and autoimmune conditions. TG Therapeutics operates primarily in the biotechnology and pharmaceuticals sectors, aiming to address unmet medical needs with innovative therapeutic solutions.
How the Company Makes MoneyTG Therapeutics generates revenue primarily through the commercialization of its FDA-approved drugs, including ublituximab and umbralisib. These products are sold to healthcare providers, hospitals, and clinics for the treatment of specific B-cell malignancies and autoimmune diseases. The company may also earn revenue from collaboration agreements, research grants, and partnerships with other pharmaceutical companies, which can provide funding and support for ongoing research and development efforts. Additionally, TG Therapeutics may receive milestone payments and royalties from licensing agreements related to its proprietary technologies and drug candidates.
TG Therapeutics Financial Statement Overview
Summary
TG Therapeutics shows a volatile financial performance with significant fluctuations in revenue and profitability. While there are signs of improvement in equity and cash flow management, the company's financial health is undermined by erratic income generation and high leverage. The balance sheet appears more stable in 2024, yet historical financial instability poses a risk.Income Statement
Revenue fluctuated significantly, with a peak in 2023 but a complete drop in 2024. The gross profit margin was high in 2023 but virtually non-existent in 2024 due to zero revenue. The EBIT and EBITDA margins showed improvement in 2023 but turned negative in 2022 and 2021, indicating instability in operational efficiency.45
Neutral
Balance Sheet
The company's debt-to-equity ratio improved in 2024 due to an increase in stockholders' equity, but high liabilities compared to assets remain a concern. The equity ratio is positive, reflecting a healthier balance sheet in 2024, but the company has experienced negative equity in previous years, highlighting financial instability and risk.55
Neutral
Cash Flow
The operating cash flow remained negative, indicating ongoing operational challenges. Free cash flow improved slightly in 2023 but turned negative again in 2024. The operating cash flow to net income ratio suggests reliance on financing activities to sustain operations.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 329.00M | 233.66M | 2.79M | 6.69M | 152.00K | Gross Profit |
| 290.52M | 219.11M | 2.52M | 5.90M | -222.00K | EBIT |
| 41.93M | 20.63M | -192.84M | -344.77M | -273.59M | EBITDA |
| 49.90M | 26.10M | -187.63M | -341.97M | -272.68M | Net Income Common Stockholders |
| 23.38M | 12.67M | -203.83M | -355.55M | -285.88M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 311.00M | 217.51M | 174.08M | 350.30M | 605.43M | Total Assets |
| 577.69M | 329.59M | 193.57M | 379.63M | 625.64M | Total Debt |
| 253.72M | 110.80M | 83.06M | 79.05M | 41.98M | Net Debt |
| 73.83M | 17.86M | -19.24M | -219.84M | -511.46M | Total Liabilities |
| 355.33M | 169.09M | 134.99M | 142.48M | 106.29M | Stockholders Equity |
| 222.36M | 160.50M | -1.53B | -1.33B | 519.35M |
| Cash Flow | Free Cash Flow | |||
| -40.52M | -31.41M | -176.18M | -296.04M | -214.86M | Operating Cash Flow |
| -40.52M | -31.41M | -176.17M | -295.63M | -214.51M | Investing Cash Flow |
| -1.04M | -50.65M | -20.01M | -332.00K | -24.51M | Financing Cash Flow |
| 128.53M | 72.70M | -391.00K | 41.42M | 679.83M |
TG Therapeutics Technical Analysis
Positive
37.55
Price Trends
31.55
Positive
30.65
Positive
25.62
Positive
Market Momentum
1.66
Negative
66.18
Neutral
89.01
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGTX, the sentiment is Positive. The current price of 37.55 is above the 20-day moving average (MA) of 32.46, above the 50-day MA of 31.55, and above the 200-day MA of 25.62, indicating a bullish trend. The MACD of 1.66 indicates Negative momentum. The RSI at 66.18 is Neutral, neither overbought nor oversold. The STOCH value of 89.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TGTX.
TG Therapeutics Risk Analysis
TG Therapeutics disclosed 75 risk factors in its most recent earnings report. TG Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TG Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $6.16B | 281.02 | 12.21% | ― | 40.80% | 100.62% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
44 Neutral | $115.17M | ― | -53.54% | ― | 145.37% | 57.01% | |
42 Neutral | $110.00M | ― | -54.21% | ― | -78.55% | -0.92% | |
38 Underperform | $50.44M | ― | 260.68% | ― | 59.00% | 32.67% |
* Healthcare Sector Average
Performance Comparison
TGTX
TG Therapeutics
37.55
21.71
137.06%
AGEN
Agenus
2.05
-11.33
-84.68%
FATE
Fate Therapeutics
0.96
-6.70
-87.47%
ADAP
Adaptimmune Therapeutics
0.45
-1.04
-69.80%
TG Therapeutics Earnings Call Summary
Earnings Call Date: Mar 3, 2025 | % Change Since: 24.79% | Next Earnings Date: May 6, 2025
Earnings Call Sentiment Positive
The earnings call reflects strong performance and growth in revenue, successful product launches, and positive clinical developments. However, challenges remain with competitive market pressures and ongoing development of the subcutaneous formulation.Highlights
Record-Breaking Revenue and Growth
Full year 2024 U.S. revenues of $310 million exceeded target guidance, marking approximately 250% growth versus 2023. Q4 U.S. net sales were $103.6 million, representing 24% growth quarter-over-quarter.
Successful Launch and Expansion of BRIUMVI
BRIUMVI was successfully launched in various EU countries and the U.K. through partner Neuraxpharm, with positive feedback from the EU market.
Positive Clinical Data and Development
Updated data from the ENHANCE study showed consistent safety and tolerability with a 30-minute infusion. Preliminary data supports a potential subcutaneous formulation with at least every other month dosing.
Patent Protection and Pipeline Expansion
Three new patents issued in 2024 provide protection for BRIUMVI through 2042. Partnership with Precision BioSciences to develop azer-cel for autoimmune diseases was announced.
Lowlights
Competitive Market Challenges
Despite growth, BRIUMVI faces a competitive market with a new entrant and existing competitors like Ocrevus.
Subcutaneous Formulation Development
The trial design for the subcutaneous formulation is still being finalized, with questions on dosing intervals remaining.
Company Guidance
In the recent conference call, TG Therapeutics provided guidance that highlighted significant achievements and future plans for BRIUMVI. For fiscal year 2024, the company reported U.S. revenues of $310 million, exceeding their target, and projected strong growth into 2025 with a revenue estimate of $525 million. The company discussed the successful launch of BRIUMVI in the U.S. and Europe, with a significant 160% growth in fourth-quarter U.S. net sales year-over-year. Further, TG Therapeutics emphasized their strategic focus on enhancing patient experience by developing a subcutaneous formulation of BRIUMVI, targeting a pivotal trial initiation by mid-2025. The guidance also outlined plans for clinical trials, including a Phase 1 study for BRIUMVI in myasthenia gravis and an exploratory study for azer-cel in multiple sclerosis. Operating expenses for 2024 were well-controlled at $206 million, and the company is financially positioned with $311 million in cash to support ongoing initiatives. Overall, TG Therapeutics expressed confidence in their ability to sustain growth and expand BRIUMVI's market presence.TG Therapeutics Corporate Events
Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
TG Therapeutics Reports Strong Revenue and Future Goals
Positive
Jan 14, 2025
On January 14, 2025, TG Therapeutics announced preliminary U.S. net product revenue for BRIUMVI, reporting $103.6 million for Q4 and $310 million for the full year 2024, exceeding expectations. The company also presented its 2025 guidance, targeting $540 million in global revenue, primarily driven by BRIUMVI sales, and outlined development milestones, including trials for subcutaneous administration and further indications for BRIUMVI beyond MS, positioning it as a significant player in the biotechnology sector.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.